Guillermo Garcia-Manero MD

Hematologic Oncology

Professor, Hematology, University of Texas Medical School at Houston

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Garcia-Manero is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Garcia-Manero's full profile Already have an account?

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1996 - 1999
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1993 - 1996
Universidad de Zaragoza Faculty of MedicineClass of 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2027
GA State Medical License 2024 - 2027
MS State Medical License 2024 - 2027
OK State Medical License 2020 - 2027
TN State Medical License 2024 - 2027
AL State Medical License 2024 - 2026
LA State Medical License 2024 - 2026
TX State Medical License 2000 - 2026
WA State Medical License 2024 - 2026
PA State Medical License 1994 - 2014
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
America's Top Doctors for Cancer Castle Connolly, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes Start of enrollment: 2004 Jan 23
COMPLETED
PHASE1, PHASE2
Phase II 5-Azacytidine Plus VPA Plus ATRA
COMPLETED
PHASE2
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
COMPLETED
PHASE1

Publications & Presentations

PubMed

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.
Aziz Farhat, Georgina El Hajjar, Hagop Kantarjian, Koji Sasaki, Nicholas J Short
Cancer. 2026-08-15
Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption, and Dismal Prognosis.
Qing Wei, L Jeffrey Medeiros, Sanam Loghavi, Jake S Leighton, Shimin Hu
Modern Pathology. 2026-08-01
Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring.
Trevor Jamison, Elias Jabbour, Omer Karrar, Nitin Jain, Fadi G Haddad
Leukemia & Lymphoma. 2026-08-01

Abstracts/Posters

Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data
Guillermo Garcia-Manero, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with ...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hematologic Improvement_Neutrophil and _Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspate...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017

Press Mentions

COMMANDS: First-Line Luspatercept Continues to Show Positive OS Trend Over Epoetin Alfa in Lower-Risk Myelodysplastic SyndromesMay 21st, 2026
Texas Medical Center Sees Wave of Leadership Changes: UTHealth, Baylor College of Medicine and MoreDecember 10th, 2025
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and ExpositionDecember 7th, 2025